13. SARAH Trial: In a single-center cohort of patients with cancer receiving anthracycline-based chemotherapy, sacubitril/valsartan reduced the risk of subclinical LV dysfunction at 6 months compared with placebo.

Here's a video I made breaking down this Cardiac Arrest Echo that was recorded during CPR #FOAMed

Fantastic news! Smoking defeated!

We always talk about diet in cardiovascular and kidney diseases. How about lung diseases? Are we what we eat? In this review with Don Sin we address this!

Cystatin C is a predictor for all-cause and cardiovascular mortality in adults with metabolic syndrome. academic.oup.com/jcem/article/1…

Comparison of the cardiorenal effects between combination therapy and monotherapy with SGLT2 inhibitors and/or GLP-1 receptor agonists. …ubs.pericles-prod.literatumonline.com/doi/10.1111/do…

Semaglutide is an option for treating obesity in patients with kidney failure on dialysis. This could significantly aid in their weight loss efforts and improve their chances of being listed for kidney transplantation. #semaglutide …ubs.pericles-prod.literatumonline.com/doi/10.1111/do…

#Bronchiectasis is characterized by neutrophilic airway inflammation. However, therapeutics that can safely target #neutrophils have been elusive, until now. This brilliant editorial explains why CatC inhibition improves health outcomes in #bronchiectasis bit.ly/3XmKrVQ

Think of LDL like ‘pack-years’ in smoking 👉🏼 Total exposure over time matters! ⏳ Lowering LDL earlier reduces plaque burden & CV events 📉 ⏰ Prevention starts now! 🫀🔥 🔗 nature.com/articles/s4156… #Lipidology #Atherosclerosis American College of Cardiology European Society of Cardiology Journals European Atherosclerosis Society #MedEd

Kudos to the authors for discussing the role of POCUS in the diagnosis of acute valvular emergencies

SGLT-2 inhibitors and GLP-1 receptor agonists are linked to a lower risk of #COPD exacerbations compared to DPP-4 inhibitors in patients with type 2 #diabetes and COPD. ja.ma/3Q9flhi Avik Ray, William Feldman

Our aim is not to diagnose a disease once it has fully manifested but to detect it in the preclinical phase, when we have a greater chance of modifying its natural history!

Here Dr. Sadatsafavi UBC Pharm Sci and I make the argument that triple inhaled therapy be considered earlier in the course of #COPD and for most (if not all) patients. bit.ly/3Nh9W6j

We did it! Absolutely thrilled to share the results of the ASPEN trial published today in NEJM Brensocatib(10mg and 25mg vs placebo) reduced exacerbations over 52 weeks and slowed lung function decline A new treatment for bronchiectasis patients nej.md/4lBHwUr

A new study published in Nicotine & Tobacco Research found that those using #ecigarettes alone were more than twice as likely to develop #COPD than people who didn’t use any tobacco products, with an even higher risk for those who mix e-cigarettes and traditional cigarettes.

What is type 2 airway inflammation in #COPD? Here, we perform bronchoscopy and endophenotype patients and show that pts with increased BAL #eosinophils respond to #ICS. Using blood #eos is useless. bit.ly/3Wvyw8v

New study result 🚨 Tirzepatide vs semaglutide SURMOUNT 5 RCT 📉Total body weight loss: −20.2% with tirzepatide −13.7% with semaglutide 🤢Discontinuations due to gastrointestinal events: tirzepatide 2.7%, semaglutide 5.6% 🤮vomiting tirzepatide 15.0% vs semaglutide 21.3%

🚨 Can echocardiography really exclude HFpEF? New data say: not reliably. A large, invasive hemodynamics–validated study tested the updated 2025 ASE diastolic function grading algorithm in patients with confirmed HFpEF — and the results are eye-opening. 👀 🔍 Key finding: Among